Travaux scientifiques

Prof. Dr. İrfan Çiçin

318 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

    BMC Cancer, 2024

    DOI 10.1186/s12885-023-11213-6 PMID 39054485 20 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  2. Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102282 PMID 39709686 2 citations (Europe PMC) Source : OpenAlex

  3. Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer

    JCO Global Oncology, 2024

    DOI 10.1200/go.24.00201 PMID 39208383 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  4. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2403051 PMID 39257075 2 citations (Europe PMC) Source : OpenAlex

  5. Potential predictor of prognosis in breast carcinoma: Tumor budding

    Indian Journal of Pathology and Microbiology, 2024

    DOI 10.4103/ijpm.ijpm_300_24 PMID 40682770 Texte intégral en libre accèsSource : OpenAlex

  6. A Perspective: The Integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for Phase II Immunotherapy Clinical Trials

    Immunotherapy, 2024

    DOI 10.2217/imt-2023-0184 PMID 38197142 1 citation (Europe PMC) Source : OpenAlex

  7. Pilomatrix Carcinoma with Pulmonary Metastasis

    Journal of Oncological Sciences, 2024

    DOI 10.37047/jos.2023-99357 4 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  8. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.103 11 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  9. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.17_suppl.lba8500 8 citations (OpenAlex) Source : OpenAlex

  10. Abstract PO3-04-12: SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i

    Cancer Research, 2024

    DOI 10.1158/1538-7445.sabcs23-po3-04-12 3 citations (OpenAlex) Source : OpenAlex

  11. Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.4109 3 citations (OpenAlex) Source : OpenAlex

  12. Perceptions and expectations: A study on prognostic perception and quality of life in patients with metastatic renal and bladder cancer.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.e16505 Source : OpenAlex

  13. GENERAL PRINCIPLES OF IMMUNOTHERAPY FOR SOLID TUMORS

    Turkiye Klinikleri eBooks, 2024

    DOI 10.5336/978-625-395-244-0_p1 Texte intégral en libre accèsSource : OpenAlex

  14. Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis

    2024

    DOI 10.20944/preprints202412.2185.v1 Texte intégral en libre accèsSource : ORCID

  15. Overview of Clinical, Pathological and Treatment Features of the Patients with Endometrium Cancer: A Single Center Study

    Eurasian Journal of Medical Advances, 2024

    DOI 10.14744/ejma.2024.83792 Texte intégral en libre accèsSource : ORCID

  16. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

    Biomolecules and Biomedicine, 2023

    DOI 10.17305/bb.2023.9253 PMID 37289436 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  17. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

    BMC Cancer, 2023

    DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  18. Major and minor salivary gland cancers: A multicenter retrospective study

    Head & Neck, 2023

    DOI 10.1002/hed.27376 PMID 37084179 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  19. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

    Journal of Cancer Research and Clinical Oncology, 2023

    DOI 10.1007/s00432-023-05190-3 PMID 37480524 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  20. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.23.00515 PMID 37379502 131 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  21. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

    The Lancet Oncology, 2023

    DOI 10.1016/s1470-2045(23)00329-7 PMID 37591293 96 citations (Europe PMC) Source : OpenAlex

  22. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

    Journal of Thoracic Oncology, 2023

    DOI 10.1016/j.jtho.2023.08.018 PMID 37597750 85 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  23. Cancer-related hypercalcemia and potential treatments

    Frontiers in Endocrinology, 2023

    DOI 10.3389/fendo.2023.1039490 PMID 37033238 39 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  24. Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

    Journal of Thoracic Oncology, 2023

    DOI 10.1016/j.jtho.2023.08.017 PMID 37865896 29 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  25. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer

    Therapeutic Advances in Medical Oncology, 2023

    DOI 10.1177/17588359231151840 PMID 36756142 16 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  26. Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer

    Current Issues in Molecular Biology, 2023

    DOI 10.3390/cimb45100491 PMID 37886935 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  27. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer

    PLoS ONE, 2023

    DOI 10.1371/journal.pone.0283445 PMID 37428725 6 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  28. PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

    Journal of Clinical Medicine, 2023

    DOI 10.3390/jcm12196420 PMID 37835062 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  29. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

    Acta Oncologica, 2023

    DOI 10.1080/0284186x.2023.2202330 PMID 37083566 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  30. Coexistence of Anti-PD1-Induced Immune Myocarditis and Complete Atrioventricular Block: A Case Report

    The American Journal of Cardiology, 2023

    DOI 10.1016/j.amjcard.2023.08.058 PMID 37722199 3 citations (Europe PMC) Source : OpenAlex

  31. Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

    Cancer Medicine, 2023

    DOI 10.1002/cam4.6664 PMID 37935428 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  32. Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye

    Future Oncology, 2023

    DOI 10.2217/fon-2023-0518 PMID 38014519 Texte intégral en libre accèsSource : OpenAlex

  33. Is the “ P -value” Alone a Sufficient Metric for the Magnitude of Clinical Benefit and Which Clinical Trial Is Actually Positive, KEYNOTE-394 or KEYNOTE-240?

    The Oncologist, 2023

    DOI 10.1093/oncolo/oyad145 PMID 37294662 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  34. An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea

    TURKISH JOURNAL OF MEDICAL SCIENCES, 2023

    DOI 10.55730/1300-0144.5557 PMID 36945921 Texte intégral en libre accèsSource : OpenAlex

  35. Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.4504 47 citations (OpenAlex) Source : OpenAlex

  36. Abstract GS1-09: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

    Cancer Research, 2023

    DOI 10.1158/1538-7445.sabcs22-gs1-09 3 citations (OpenAlex) Source : OpenAlex

  37. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.9022 3 citations (OpenAlex) Source : OpenAlex

  38. Awareness and perceptions of clinical trials in patients with cancer and their families in Turkey.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.e18780 1 citation (OpenAlex) Source : OpenAlex

  39. Patient preferences for use of archived biospecimens in Turkey.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.e18904 Texte intégral en libre accèsSource : OpenAlex

  40. Clinical and Radiological Features and Treatment of Pulmonary Toxicity Associated with Using Immune Checkpoint Inhibitors in Cancer Treatment: A Single-Center Experience

    Journal of Oncological Sciences, 2023

    DOI 10.37047/jos.2023-95972 Texte intégral en libre accèsSource : OpenAlex

  41. Comparison of Extrapulmonary Small Cell Carcinoma and Small Cell Lung Carcinoma: A Single-Center Study

    Journal of Oncological Sciences, 2023

    DOI 10.37047/jos.2023-97197 Texte intégral en libre accèsSource : OpenAlex

  42. O10-2 Telisotuzumab vedotin monotherapy in Asian patients with c-Met–overexpressing advanced non-small cell lung cancer

    Annals of Oncology, 2023

    DOI 10.1016/j.annonc.2023.09.134 Texte intégral en libre accèsSource : OpenAlex

  43. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e15562 Source : OpenAlex

  44. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e12610 2 citations (OpenAlex) Source : OpenAlex

  45. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study

    Medicine, 2022

    DOI 10.1097/md.0000000000030147 PMID 36107512 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  46. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

    The Lancet Oncology, 2022

    DOI 10.1016/s1470-2045(22)00694-5 PMID 36493792 534 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  47. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

    JAMA, 2022

    DOI 10.1001/jama.2022.16464 PMID 36166026 454 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  48. Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

    Cancer, 2022

    DOI 10.1002/cncr.34477 PMID 36308296 18 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  49. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

    European Urology Open Science, 2022

    DOI 10.1016/j.euros.2022.08.018 PMID 36353661 13 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  50. ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

    Critical Reviews in Oncology/Hematology, 2022

    DOI 10.1016/j.critrevonc.2022.103847 PMID 36257531 9 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex